Mari Ariyasu

Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial

Matteo Bassetti, Roger Echols, Yuko Matsunaga et al. · The Lancet Infectious Diseases · 2020 · 792 citations

Life Sciences, Infectious Diseases, Microbiology +14

Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial

Richard G. Wunderink, Yuko Matsunaga, Mari Ariyasu et al. · The Lancet Infectious Diseases · 2020 · 464 citations

Pharmacy, Clinical Sciences, Infectious Diseases +17

Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial

Simon Portsmouth, David van Veenhuyzen, Roger Echols et al. · The Lancet Infectious Diseases · 2018 · 404 citations

Life Sciences, Infectious Diseases, Microbiology +10

Prevalence of Carbapenem-Resistant Gram-Negative Infections in the United States Predominated by Acinetobacter baumannii and Pseudomonas aeruginosa

Bin Cai, Roger Echols, Glenn Magee et al. · Open Forum Infectious Diseases · 2017 · 197 citations · Full text

Life Sciences, Infectious Diseases, Microbiology +17

Compassionate Use of Cefiderocol as Adjunctive Treatment of Native Aortic Valve Endocarditis Due to Extremely Drug-resistant Pseudomonas aeruginosa

Jonathan D. Edgeworth, Domenico Merante, Sanjay Patel et al. · Clinical Infectious Diseases · 2018 · 64 citations · Full text

Life Sciences, Infectious Diseases, Microbiology +17